MassMutual Private Wealth & Trust FSB Acquires 58 Shares of United Therapeutics Co. (NASDAQ:UTHR)

MassMutual Private Wealth & Trust FSB raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 31.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 240 shares of the biotechnology company’s stock after purchasing an additional 58 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in United Therapeutics were worth $85,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of UTHR. World Investment Advisors LLC bought a new stake in shares of United Therapeutics in the 3rd quarter worth about $139,206,000. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after acquiring an additional 152,249 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of United Therapeutics by 32.5% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock worth $123,181,000 after acquiring an additional 84,369 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on UTHR shares. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Stock Up 0.2 %

Shares of United Therapeutics stock opened at $371.89 on Friday. The firm’s 50 day moving average price is $365.04 and its 200-day moving average price is $355.24. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company has a market cap of $16.60 billion, a P/E ratio of 16.33, a PEG ratio of 0.94 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the firm earned $5.38 EPS. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the sale, the chief financial officer now owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,848 shares of company stock valued at $55,165,099 in the last 90 days. Insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.